Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- 29 July 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (15), 4799-4805
- https://doi.org/10.1158/1078-0432.ccr-08-0125
Abstract
Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the rapidly evolving therapeutic implications of targeting it. In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers.Keywords
This publication has 70 references indexed in Scilit:
- Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisNature Genetics, 2009
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- Structural comparisons of class I phosphoinositide 3-kinasesNature Reviews Cancer, 2008
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patientsBritish Journal of Cancer, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005